Cargando…

Genetic epidemiology of dengue viruses in phase III trials of the CYD tetravalent dengue vaccine and implications for efficacy

This study defined the genetic epidemiology of dengue viruses (DENV) in two pivotal phase III trials of the tetravalent dengue vaccine, CYD-TDV, and thereby enabled virus genotype-specific estimates of vaccine efficacy (VE). Envelope gene sequences (n = 661) from 11 DENV genotypes in 10 endemic coun...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rabaa, Maia A, Girerd-Chambaz, Yves, Duong Thi Hue, Kien, Vu Tuan, Trung, Wills, Bridget, Bonaparte, Matthew, van der Vliet, Diane, Langevin, Edith, Cortes, Margarita, Zambrano, Betzana, Dunod, Corinne, Wartel-Tram, Anh, Jackson, Nicholas, Simmons, Cameron P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	eLife Sciences Publications, Ltd 2017
Materias:	Epidemiology and Global Health
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5584992/ https://www.ncbi.nlm.nih.gov/pubmed/28871961 http://dx.doi.org/10.7554/eLife.24196

Ejemplares similares

CYD Tetravalent Dengue Vaccine Performance by Baseline Immune Profile (Monotypic/Multitypic) in Dengue-Seropositive Individuals
por: DiazGranados, Carlos A, et al.
Publicado: (2020)

Analysis of Hospitalized and Severe Dengue Cases Over the 6 years of Follow-up of the Tetravalent Dengue Vaccine (CYD-TDV) Efficacy Trials in Asia and Latin America
por: Forrat, Rémi, et al.
Publicado: (2021)

Dengue seroprevalence: data from the clinical development of a tetravalent dengue vaccine in 14 countries (2005–2014)
por: L’Azou, Maïna, et al.
Publicado: (2018)

Microneutralization assay titer correlates analysis in two phase 3 trials of the CYD-TDV tetravalent dengue vaccine in Asia and Latin America
por: Carpp, Lindsay N., et al.
Publicado: (2020)

Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adults
por: Kirstein, Judith, et al.
Publicado: (2018)

Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2–45 years: Phase II randomized controlled trial in Singapore
por: Sin Leo, Yee, et al.
Publicado: (2012)

Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico
por: Dayan, Gustavo H, et al.
Publicado: (2014)

Long-term immunogenicity and safety of tetravalent dengue vaccine (CYD-TDV) in healthy populations in Singapore and Vietnam: 4-year follow-up of randomized, controlled, phase II trials
por: Tran, Ngoc Huu, et al.
Publicado: (2019)

Efficacy profile of the CYD-TDV dengue vaccine revealed by Bayesian survival analysis of individual-level phase III data
por: Laydon, Daniel J, et al.
Publicado: (2021)

Secondary Analysis of the Efficacy and Safety Trial Data of the Tetravalent Dengue Vaccine in Children and Adolescents in Colombia
por: Reynales, Humberto, et al.
Publicado: (2020)

Clinical Efficacy, Safety, and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine (CYD-TDV) in Children: A Systematic Review with Meta-analysis
por: Malisheni, Moffat, et al.
Publicado: (2017)

Efficacy, immunogenicity and safety of a recombinant tetravalent dengue vaccine (CYD-TDV) in children aged 2–17 years: systematic review and meta-analysis
por: Rosa, Bruno Rodrigues, et al.
Publicado: (2019)

Zika and Dengue Interactions in the Context of a Large Dengue Vaccine Clinical Trial in Latin America
por: Zambrano, Betzana, et al.
Publicado: (2021)

Safety Overview of a Recombinant Live-Attenuated Tetravalent Dengue Vaccine: Pooled Analysis of Data from 18 Clinical Trials
por: Gailhardou, Sophia, et al.
Publicado: (2016)

Chikungunya and Zika Virus Cases Detected against a Backdrop of Endemic Dengue Transmission in Vietnam
por: Quyen, Nguyen Than Ha, et al.
Publicado: (2017)

A29 Wolbachia for dengue control; will dengue viruses evolve resistance?
por: Vi, T.T., et al.
Publicado: (2017)

Effect of the Tetravalent Dengue Vaccine TAK-003 on Sequential Episodes of Symptomatic Dengue
por: Sáez-Llorens, Xavier, et al.
Publicado: (2023)

Sensitivity and Specificity of a Novel Classifier for the Early Diagnosis of Dengue
por: Tuan, Nguyen Minh, et al.
Publicado: (2015)

An Evidence-Based Algorithm for Early Prognosis of Severe Dengue in the Outpatient Setting
por: Nguyen, Minh Tuan, et al.
Publicado: (2017)

Integrated immunogenicity analysis of a tetravalent dengue vaccine up to 4 y after vaccination
por: Vigne, Claire, et al.
Publicado: (2017)

Households as Foci for Dengue Transmission in Highly Urban Vietnam
por: Anders, Katherine L., et al.
Publicado: (2015)

Immunogenicity and safety of a tetravalent dengue vaccine in dengue-naïve adolescents in Mexico City
por: Biswal, Shibadas, et al.
Publicado: (2021)

Economic Impact of Dengue Illness in the Americas
por: Shepard, Donald S., et al.
Publicado: (2011)

Refined efficacy estimates of the Sanofi Pasteur dengue vaccine CYD-TDV using machine learning
por: Dorigatti, I., et al.
Publicado: (2018)

Genetic variants of MICB and PLCE1 and associations with the laboratory features of dengue
por: Whitehorn, James, et al.
Publicado: (2017)

A tetravalent dengue nanoparticle stimulates antibody production in mice
por: Silva, Elisângela F, et al.
Publicado: (2012)

Current Development and Challenges of Tetravalent Live-Attenuated Dengue Vaccines
por: Hou, Jue, et al.
Publicado: (2022)

Consumer Willingness to Pay for Dengue Vaccine (CYD-TDV, Dengvaxia(®)) in Brazil; Implications for Future Pricing Considerations
por: Godói, Isabella P., et al.
Publicado: (2017)

Genetic Variants of MICB and PLCE1 and Associations with Non-Severe Dengue
por: Whitehorn, James, et al.
Publicado: (2013)

Simulations to compare efficacies of tetravalent dengue vaccines and mosquito vector control
por: THAVARA, U., et al.
Publicado: (2014)

Challenges to the Design of Clinical Trials for Live-Attenuated Tetravalent Dengue Vaccines
por: Russell, Philip K., et al.
Publicado: (2016)

Design of Monovalent and Chimeric Tetravalent Dengue Vaccine Using an Immunoinformatics Approach
por: Dixit, Neeraj Kumar
Publicado: (2021)

Efficacy of Tetravalent Dengue Vaccine: A Systematic Review and Meta-Analysis
por: Khobragade, Ashish Wasudeo, et al.
Publicado: (2021)

Development of MVA-d34 Tetravalent Dengue Vaccine: Design and Immunogenicity
por: Mintaev, Ramil R., et al.
Publicado: (2023)

Immunogenicity and safety of a tetravalent dengue vaccine in healthy adults in India: A randomized, observer-blind, placebo-controlled phase II trial
por: Dubey, Anand Prakash, et al.
Publicado: (2015)

Microvascular Fluid Exchange: Implications of the Revised Starling Model for Resuscitation of Dengue Shock Syndrome
por: Trung, Dinh The, et al.
Publicado: (2020)

Induction of Neutralizing Antibodies against Four Serotypes of Dengue Viruses by MixBiEDIII, a Tetravalent Dengue Vaccine
por: Zhao, Hui, et al.
Publicado: (2014)

Resource Use and Costs of Dengue: Analysis of Data from Phase III Efficacy Studies of a Tetravalent Dengue Vaccine
por: El Fezzazi, Hanna, et al.
Publicado: (2017)

Predicting outcome from dengue
por: Yacoub, Sophie, et al.
Publicado: (2014)

Corticosteroids for Dengue – Why Don't They Work?
por: Nguyen, Thi Hanh Tien, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_rb4sbl8b2fg57d08372ivf4n6r